Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

Academic Article


  • The purpose of this phase I study was to evaluate the safety and immunogenicity of 2 doses of cytomegalovirus glycoprotein B (CMV gB)/MF59 vaccine at 3 different immunization schedules. Ninety-five volunteers were randomized to 6 groups. Antibodies to gB represent the majority of the CMV- specific neutralizing response. Three groups received 5 μg of gB antigen combined with MF59 (a proprietary adjuvant) and 3 groups received a 30-μg dose at 0, 1, and 2 months; 0, 1, and 4 months; or 0, 1, and 6 months. The vaccine was well tolerated, and there was no significant difference in antibody production between the 2 doses. The vaccine induced highest antibody titers when given at 0, 1, and 6 months. A low dose of CMV gB/MF59 may be the preferred dose for future studies.
  • Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 17491118
  • Author List

  • Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL
  • Start Page

  • 1700
  • End Page

  • 1703
  • Volume

  • 180
  • Issue

  • 5